HealthTree Logo
search more_vert
App Logo
close
person Sign In / Create Account
New Trial in Boston Using a Checkpoint Inhibitor in Smoldering Myeloma
Posted: Sep 19, 2016
New Trial in Boston Using a Checkpoint Inhibitor in Smoldering Myeloma image

A new class of drugs is entering myeloma clinical trials. These checkpoint inhibitors take the "brakes" off the immune system so it can do it's job to kill the myeloma cells. To learn more about how this class of drugs works, click here. This new drug, called nivolumab, is now being tested in a Phase II clinical trial in combination with dexamethasone and lenalidomide to determine if it can help prevent or postpone smoldering myeloma from progressing to active myeloma. The trial will enroll 41 patients and will be open in both Beth Israel Deaconess Medical Center and the Dana Farber Cancer Institute in Boston. Click here to learn more about the clinical trial: Nivolumab, Rev, Dex Smoldering Myeloma Clinical Trial

The author Jennifer Ahlstrom

about the author
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of Myeloma Crowd by HealthTree and the HealthTree Foundation.

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Abbvie
Genentech
GSK
Bristol Myers Squibb

Follow Us

facebook instagram twitter youtube